IPCI - IntelliPharmaCeutics International Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.392
-0.033 (-7.68%)
As of 10:15AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.425
Open0.391
Bid0.391 x 1000
Ask0.400 x 1000
Day's Range0.391 - 0.400
52 Week Range0.320 - 2.920
Volume18,543
Avg. Volume256,770
Market Cap16.548M
Beta0.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017
    Capital Cube7 months ago

    Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Intellipharmaceutics International, Inc. reports financial results for the quarter ended August 31, 2017. Highlights Summary numbers: Revenues of USD 1.19 million, Net Earnings of USD -2.55 million. Change in operating cash flow of 62.25% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • New Strong Sell Stocks for October 11th
    Zacks7 months ago

    New Strong Sell Stocks for October 11th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Associated Press7 months ago

    Intellipharmaceutics reports 3Q loss

    The Toronto-based company said it had a loss of 8 cents per share. The extended-release drug developer posted revenue of $1.2 million in the period. In the final minutes of trading on Tuesday, the company's ...

  • Reuters8 months ago

    FDA declines to approve Intellipharma's opioid painkiller

    Intellipharmaceutics International Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its long-acting opioid painkiller in its current form, backing its independent advisory panel that had raised concerns over the drug's abuse-deterrence capabilities. The decision comes at a time when the United States is battling with the opioid abuse crisis, which claimed more than 33,000 people in 2015, according to the Centers for Disease Control and Prevention. The FDA asked Intellipharma to complete additional studies to assess the abuse-deterrent properties of the drug when used via oral and nasal methods, the company said.

  • Newsfile10 months ago

    IIROC Trade Resumption - Intellipharmaceutics International Inc.

    Toronto, Ontario--(Newsfile Corp. - July 27, 2017) - Trading resumes in: Company: Intellipharmaceutics International Inc. TSX Symbol: IPCI (All issues) ...

  • Reuters10 months ago

    FDA panel votes against approving Intellipharma's opioid painkiller

    A panel of independent advisers to the U.S. Food and Drug Administration concluded on Wednesday that there is not enough evidence to support the approval of Intellipharmaceutics International Inc's long-acting opioid painkiller. Toronto-based Intellipharma's painkiller has been developed as a unique abuse-deterrent version of Purdue Pharma's oft-abused blockbuster OxyContin, which already has tamper-resistant properties. In a preliminary review on Monday, FDA scientists raised concerns that Intellipharma had not provided adequate data on the abuse potential of the drug as part of its U.S. marketing application.

  • Reuters10 months ago

    Abuse-liability data on Intelli's opioid drug missing - FDA staff

    U.S. Food and Drug Administration scientists on Monday raised concerns that Intellipharmaceutics International Inc failed to provide data from studies testing the abuse potential of its long-acting opioid painkiller. Canada-based Intellipharma's product, Rexista, has been developed as a unique abuse-deterrent version of Purdue Pharma's OxyContin, which already has tamper-resistance properties. In a preliminary review posted ahead of a meeting of independent advisers on Wednesday, FDA scientists said that abuse-liability data had not been submitted as part of Rexista's marketing application.

  • Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q2, 2017 By the Numbers : July 14, 2017
    Capital Cube10 months ago

    Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q2, 2017 By the Numbers : July 14, 2017

    Categories: Yahoo FinanceGet free summary analysis Intellipharmaceutics International, Inc. reports financial results for the quarter ended May 31, 2017. Highlights Summary numbers: Revenues of USD 2.00 million, Net Earnings of USD -1.81 million. Change in operating cash flow of 35.24% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • Associated Press10 months ago

    Intellipharmaceutics reports 2Q loss

    On a per-share basis, the Toronto-based company said it had a loss of 6 cents. The extended-release drug developer posted revenue of $2 million in the period. In the final minutes of trading on Tuesday, ...

  • Key FDA Events to Watch Out for in Jul 2017
    Zacks11 months ago

    Key FDA Events to Watch Out for in Jul 2017

    Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?

  • Intellipharmaceutics Announces Launch of Generic Seroquel XR
    Zacks11 months ago

    Intellipharmaceutics Announces Launch of Generic Seroquel XR

    Intellipharmaceutics International Inc. (IPCI) announced the launch of a generic version of schizophrenia drug Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited Company